{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:42:43Z","timestamp":1785195763808,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Valproic acid (VPA) is not only an antiepileptic drug but also a mood stabilizer for patients with bipolar disorder. Long-term VPA therapy can cause carnitine deficiency, which may result in an increase in the blood ammonia level, in patients with epilepsy. However, information about this effect in patients with bipolar disorder is limited. The aim of this study was to investigate the associations between the serum VPA level and the carnitine and ammonia levels in psychiatric adult patients with epilepsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The subjects were 182 consecutive Japanese adult patients (mean age 54.3 \u00b1 19.5 years) diagnosed with bipolar disorder and treated with VPA. The serum VPA level, carnitine fraction, and plasma ammonia level were measured. Furthermore, the free carnitine and acylcarnitine fractions were measured using an enzyme cycling method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty-nine patients (38%) had a low free carnitine level. There were significant differences in sex, height, VPA dose, serum VPA level, total carnitine level, acylcarnitine level, and acylcarnitine\/free carnitine ratio between patients with a low free carnitine level and those with a normal range of free carnitine. The simple and multiple regression analyses revealed that the VPA dose and the serum VPA level were inversely and significantly correlated with the free carnitine level. The plasma ammonia level was correlated with the VPA dose, serum VPA level, and acylcarnitine level but not with the free carnitine level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder. However, it is unlikely that carnitine deficiency is associated with hyperammonemia in patients with bipolar disorder.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000778","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T05:01:48Z","timestamp":1595480508000},"page":"766-770","source":"Crossref","is-referenced-by-count":13,"title":["Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder"],"prefix":"10.1097","volume":"42","author":[{"given":"Saaya","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi ;"},{"name":"Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Nakagami","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Nakagami Mental Clinic, Odate, Akita ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, Aomori ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Minato Hospital, Hachinohe, Aomori ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Tarakita","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Mutsu General Hospital, Mutsu, Aomori ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Odate General Hospital, Odate, Akita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genom"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1528-1157.1992.tb01708.x","article-title":"Is 2- propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?","volume":"33","author":"Kondo","year":"1992","journal-title":"Epilepsia"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"217269","DOI":"10.1155\/2014\/217269","article-title":"Hyperammonemia associated with valproic acid concentrations","volume":"2014","author":"V\u00e1zquez","year":"2014","journal-title":"Biomed Res Int."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.1992.tb05085.x","article-title":"Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma","volume":"86","author":"Verbiest","year":"1992","journal-title":"Acta Neurol Scand."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/088307389100600102","article-title":"Carnitine, valproate, and toxicity","volume":"6","author":"Coulter","year":"1991","journal-title":"J Child Neurol."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/iub.1646","article-title":"Significance of l-carnitine for human health","volume":"69","author":"Adeva-Andany","year":"2017","journal-title":"IUBMB Life"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s005990050060","article-title":"Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs","volume":"29","author":"Verrotti","year":"1999","journal-title":"Int J Clin Lab Res."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.braindev.2010.12.003","article-title":"Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS\/MS","volume":"33","author":"Nakajima","year":"2011","journal-title":"Brain Dev."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.braindev.2005.11.005","article-title":"Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet","volume":"28","author":"Coppola","year":"2006","journal-title":"Brain Dev."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1469-8749.1991.tb14963.x","article-title":"Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs","volume":"33","author":"Thom","year":"1991","journal-title":"Dev Med Child Neurol."},{"key":"R15-20230928","first-page":"999","article-title":"The effect of valproic acid on plasma carnitine levels","volume":"145","author":"Opala","year":"1991","journal-title":"Am J Dis Child."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.braindev.2019.02.010","article-title":"Serum carnitine levels of children with epilepsy: related factors including valproate","volume":"41","author":"Okumura","year":"2019","journal-title":"Brain Dev."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"2920108","DOI":"10.1155\/2016\/2920108","article-title":"Carnitine and\/or acetylcarnitine deficiency as a cause of higher levels of ammonia","volume":"2016","author":"Maldonado","year":"2016","journal-title":"Biomed Res Int."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4088\/JCP.v66n0502","article-title":"Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study","volume":"66","author":"Moreno","year":"2005","journal-title":"J Clin Psychiat."},{"key":"R19-20230928","first-page":"622","article-title":"Colorimetric determination method of blood ammonia","volume":"21","author":"Okuda","year":"1966","journal-title":"Saishinigaku."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0887-8994(02)00460-5","article-title":"Carnitine level in Chinese epileptic patients taking sodium valproate","volume":"28","author":"Fung","year":"2003","journal-title":"Pediatr Neurol."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.braindev.2014.12.004","article-title":"Carnitine deficiency: risk factors and incidence in children with epilepsy","volume":"37","author":"Fukuda","year":"2015","journal-title":"Brain Dev."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MD.0000000000000066","article-title":"Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy","volume":"93","author":"Tseng","year":"2014","journal-title":"Medicine (Baltimore)."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1442-200X.1997.tb03580.x","article-title":"Carnitine depletion during total parenteral nutrition despite oral L-carnitine supplementation","volume":"39","author":"Hirose","year":"1997","journal-title":"Acta Paediatr Jpn."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13030-017-0101-0","article-title":"Association between the blood concentrations of ammonia and carnitine\/amino acid of schizophrenic patients treated with valproic acid","volume":"11","author":"Ando","year":"2017","journal-title":"Biopsychosoc Med."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0300060517703278","article-title":"L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: a case report","volume":"45","author":"Maldonado","year":"2017","journal-title":"J Int Med Res."},{"key":"R26-20230928","first-page":"18","article-title":"The effect of carnitine supplementation on hyperammonemia and carnitine deficiency treated with valproic acid in a psychiatric setting","volume":"12","author":"Nakamura","year":"2015","journal-title":"Innov Clin Neurosci."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1440-1819.2007.01656.x","article-title":"Different serum concentrations of steady-state valproic acid in two sustained-release formulations","volume":"61","author":"Yasui-Furukori","year":"2007","journal-title":"Psychiat Clin Neuros."},{"key":"R28-20230928","first-page":"139","article-title":"Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations","volume":"2","author":"Fujii","year":"2009","journal-title":"Drug Des Dev Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:05:56Z","timestamp":1695863156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000778","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}